Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.5B | $43.6B | $46.7B | $51.3B | $51.5B | $58.8B | $60.2B | $65.0B | $70.6B | $75.6B |
| Revenue growth | — | 5.1% | 7.0% | 10.0% | 0.4% | 14.0% | 2.5% | 7.9% | 8.7% | 7.1% |
| Net income | $2.89B | $2.22B | $3.79B | $3.50B | $3.75B | $6.96B | $5.64B | $5.24B | $5.76B | $6.78B |
| Net margin | 7.0% | 5.1% | 8.1% | 6.8% | 7.3% | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% |
| EPS (diluted) | $7.30 | $5.95 | $10.66 | $10.07 | $10.93 | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.65B | $5.43B | $6.76B | $7.60B | $9.23B | $8.96B | $8.52B | $9.43B | $10.5B | $12.6B |
| Capital expenditures | $2.76B | $3.02B | $3.57B | $4.16B | $2.83B | $3.58B | $4.39B | $4.74B | $4.88B | $4.94B |
| Free cash flow | $2.89B | $2.41B | $3.19B | $3.44B | $6.40B | $5.38B | $4.13B | $4.69B | $5.64B | $7.69B |
| Share buybacks | $2.75B | $2.05B | $1.53B | $1.03B | $441M | $8.21B | $7.00B | $3.81B | $6.04B | $10.1B |
| Dividends paid | — | $0.00 | $487M | $550M | $153M | $624M | $653M | $661M | $690M | $679M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $646M | $732M | $502M | $621M | $1.79B | $1.45B | $908M | $935M | $1.93B | $1.04B |
| Total assets | $33.8B | $36.6B | $39.2B | $45.1B | $47.5B | $50.7B | $52.4B | $56.2B | $59.5B | $60.7B |
| Total liabilities | $39.4B | $41.6B | $42.1B | $45.6B | — | — | — | — | — | — |
| Long-term debt | $31.2B | $32.9B | $32.0B | $33.6B | $30.8B | $34.3B | $37.7B | $37.2B | $38.3B | $41.6B |
| Shareholders' equity | -$7.30B | -$6.81B | -$4.95B | -$2.81B | $572M | -$933M | -$2.77B | -$1.77B | -$2.50B | -$6.03B |
| Retained earnings | -$6.97B | -$6.53B | -$4.57B | -$2.35B | $777M | -$532M | -$2.28B | -$1.35B | -$2.12B | -$5.72B |
| Shares (wtd avg diluted) | 396M | 372M | 355M | 348M | 344M | 329M | 295M | 276M | 262M | 239M |
Every figure is extracted from HCA Healthcare, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.